SCHEMBL4027375

SCHEMBL4027375

CCOC(=O)c1nc(-c2ccco2)n(C)c(=O)c1OCC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
ALDH1A1 P00352 6/20 0.48
KDM4E B2RXH2 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GAA P10253 2/20 0.48
HPGD P15428 2/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
TSHR P16473 1/20 0.48
ADORA2B P29275 5/20 0.47
ADORA3 P0DMS8 9/20 0.46
ADORA2A P29274 9/20 0.46
ADORA1 P30542 9/20 0.46
PKM P14618 1/20 0.45
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
POLB P06746 1/20 0.42
HSF1 Q00613 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4026364 0.78 KDM4E (0.35) ALDH1A1KDM4ESMN1; SMN2GAAHPGD
SCHEMBL4024972 0.77 ADORA3 (0.39) L3MBTL1ALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL4026347 0.75 CDC7 (0.46) L3MBTL1ALDH1A1KDM4EGAAHPGD
SCHEMBL4026168 0.75 KDM5B (0.42) L3MBTL1ALDH1A1KDM4EGAAHPGD
SCHEMBL4031544 0.74 KDM5B (0.45) L3MBTL1ALDH1A1KDM4EKMT2AMEN1
SCHEMBL22927688 0.73 CYP19A1 (0.42) ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1
SCHEMBL29434810 0.73 LMNA (0.43) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL4030138 0.72 ERCC1 (0.57) L3MBTL1ALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL27275782 0.72 KDM5B (0.40) L3MBTL1ALDH1A1KDM4EGAAKMT2A
SCHEMBL4025043 0.71 GABRA1 (0.45) ALDH1A1KDM4EADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1470113-B1 PYRIMIDINONE VIRAL POLYMERASE INHIBITORS ANGELETTI P IST RICHERCHE BIO (IT) 2009-01-07 EP disclosed
US-20050130997-A1 Pyrimidinone viral polymerase inhibitors ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2005-06-16 US disclosed
EP-1470113-A1 PYRIMIDINONE VIRAL POLYMERASE INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2004-10-27 EP disclosed
WO-2003062211-A1 PYRIMIDINONE VIRAL POLYMERASE INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130997-A1 Pyrimidinone viral polymerase inhibitors POLR2A, POLR1E, POLR2E L3MBTL1 3083/4885ALDH1A1 255/4885KDM4E 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.